Scarica l'app Stockscreener
3.51
3.31%
-0.12
Precedente Chiudi:
$3.63
Aprire:
$3.63
Volume 24 ore:
15,820
Relative Volume:
0.48
Capitalizzazione di mercato:
$41.12M
Reddito:
Utile/perdita netta:
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
1 W Prestazione:
-10.46%
1M Prestazione:
-1.13%
6M Prestazione:
+51.29%
1 anno Prestazione:
-54.71%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$3.44
$4.03
Portata 52W:
$1.98
$9.50
Nasus Pharma Ltd. Stock (NSRX) Company Profile
Nome
Nasus Pharma Ltd.
Settore
Industria
Telefono
-
Indirizzo
-
Compare NSRX vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NSRX
Nasus Pharma Ltd.
|
3.51 | 41.12M | 0 | 0 | 0 | 0.00 |
LLY
Lilly Eli Co
|
1,179.27 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 630.04B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 488.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 359.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.75 | 273.23B | 54.66B | 13.58B | 16.05B | 7.0171 |
Nasus Pharma Ltd. Borsa (NSRX) Ultime notizie
At the October 8 meeting, Nasus Pharma (NSRX) shareholders approved all agenda items except one. - Stock Titan
Nasus Pharma stock reiterated at Market Outperform by Citizens - Investing.com South Africa
Nasus Pharma stock reiterated at Market Outperform by Citizens - Investing.com
Nasus Pharma enrolls first patient in NS003 phase 1 trial - Investing.com
Nasus Pharma Enrolls First Patient in Phase 1 PK Trial of NS003 Intranasal Ondansetron for CINV and PONV - Quiver Quantitative
Nasus Pharma Announces Enrollment and Dosing of First - GlobeNewswire
Nasus Pharma CFO Eyal Rubin Resigns, Files Ownership Disclosure - kalkinemedia.com
Rubin Eyal ceases as CFO at Nasus Pharma (NSRX) - Stock Titan
New Nasus Pharma (NYSE: NSRX) share plan could dilute holders while funding anaphylaxis drug trials - Stock Titan
Nasus Pharma (NSRX) taps BTIG to sell new shares for drug trials - Stock Titan
FDA clears nasal epinephrine study for Nasus Pharma (NSRX) targeting anaphylaxis - Stock Titan
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis - GlobeNewswire
Nasus Pharma Ltd SEC Filing (Sep 14, 2026) - Stock Titan
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis - Yahoo Finance
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Nasus Pharma to Present at H.C. Wainwright 28th Annual Global Investment Conference - Quiver Quantitative
A company developing nasal allergy medicine will present in New York - Stock Titan
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
A $750,000 sale bonus? Nasus Pharma (NSRX) puts CEO pay to a shareholder vote - Stock Titan
Nasus Pharma (NYSE: NSRX) sets $50M share shelf for working capital and drug development - Stock Titan
Nasus Pharma Announces Transition of Chief Financial Officer - Yahoo Finance
Nasus Pharma (NSRX) CFO exit ushers in long-time insider as interim - Stock Titan
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update - GlobeNewswire
Nasus Pharma Appoints Pharmaceutical Industry Veteran - GlobeNewswire
Nasus Pharma (NYSE American: NSRX) taps Brendan O’Grady to lead next phase - Stock Titan
A new CEO takes charge as Nasus Pharma advances nasal anaphylaxis treatment - Stock Titan
NSRX Forecast — Price Target — Prediction for 2027 - TradingView
Nasus Pharma Announces Positive Results from Preclinical - GlobeNewswire
NSRX - Finviz
Nasus Pharma to Participate in Upcoming Investor Conferences - Yahoo Finance
NSRX: Nasus Pharma Ltd. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Nasus Pharma Advances NS002 Towards Pivotal Study Following - GlobeNewswire
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update - Yahoo Finance
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold - GlobeNewswire
Nasus Pharma to Present Topline Analysis from NS002 - GlobeNewswire
Nasus Pharma Announces Pricing of $15.0 Million Private Placement - GlobeNewswire
Nasus Pharma Ltd. Azioni (NSRX) Dati Finanziari
Non sono disponibili dati finanziari per Nasus Pharma Ltd. (NSRX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Nasus Pharma Ltd. Azioni (NSRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Teleman Dan Benjamin | Chief Executive Officer |
Apr 22 '26 |
Buy |
3.76 |
2,900 |
10,904 |
156,991 |
| Teleman Dan Benjamin | Chief Executive Officer |
Mar 31 '26 |
Buy |
2.04 |
15,000 |
30,600 |
21,246 |
6.05%
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):